Hummingbird Bioscience

Revolutionizing Cancer Treatment: Overcoming Resistance with Dual-Payload ADCs and AI-Driven Antibody Discovery Platform

Overcoming Drug Resistance with Dual-Payload ADCs: Hummingbird Bioscience is pioneering a unique strategy against drug resistance in cancer therapy by engineering multiple payloads into the same ADC. Their first dual-payload ADC, HMBD-802, combines a TOP1 inhibitor, exatecan, with an undisclosed DNA damage response inhibitor. This combination, carefully balanced with a 4:4 potency ratio, has shown promising preclinical efficacy in overcoming drug resistance. They’re also advancing traditional monoclonal antibodies like HER3-targeting HMBD-001 and VISTA-targeting HMBD-002 in clinical trials.
Versatile Platform for Multiple Therapeutic Modalities: Hummingbird Bioscience’s Rational Antibody Discovery (RAD) platform is uniquely designed to engineer highly selective antibodies for a wide range of cancer therapies, including ADCs, bispecific T-cell engagers (TCEs) and monoclonal antibodies. By using AI-powered insights and immunoengineering, the platform works to overcome challenges like tumor resistance and optimize the targeting of hard-to-drug proteins.